Nimotuzumab for Recurrent Nasopharyngeal Carcinoma

  • days left to enroll
  • participants needed
  • sponsor
    Fujian Cancer Hospital
Updated on 14 February 2022


The study assessed the clinical efficacy, and safety of the combination of Nimotuzumab administered concomitantly with intensity modulated radiation therapy(IMRT) in patients with recurrent nasopharyngeal cancer.


The clinical efficacy of Nimotuzumab combined with radiotherapy has been shown in advanced nasopharyngeal cancer, which was significantly higher than radiotherapy alone. The efficacy of radiotherapy combined with Nimotuzumab has not been confirmed in recurrent nasopharyngeal cancer.In this study, Phase II clinical trials were performed. The patients were treated with Nimotuzumab which were used concurrently with IMRT. The efficacy and toxicity will be assessed.

Condition Recurrent Nasopharyngeal Carcinoma
Treatment Nimotuzumab
Clinical Study IdentifierNCT03666221
SponsorFujian Cancer Hospital
Last Modified on14 February 2022


Yes No Not Sure

Inclusion Criteria

Patients with recurrent tumor in nasopharynx with or without relapse cervical lymph nodes more than 6 months after initial radical treatment
Recurrent nasopharyngeal cancer was confirmed by pathology, marginal recurrence can be diagnosed by imaging examinations
Age 18-70
At least one of the tumor lesions measurable
Functional Status: PS (ECOG) > 0-1
Normal Bone Marrow Function: White blood cell count > 4109/L, hemoglobin >90g/L, and platelet count >100109/L
Normal Hepatic and Renal Function: Alanine Tminotransferase (ALT)/Aspartate Aminotransferase (AST) < 2.5 times the upper limit of normal (ULN), while total bilirubin (T-Bil) < 1.5 x ULN and serum creatinine < 1.5 x ULN
Life expectancy of more than 6 months
All the patients signed the informed consent
Follow up regularly and comply with test requirements

Exclusion Criteria

Patients with recurrent cervical lymph nodes alone
Evidence of distant metastasis
The relapse tumor has been treated with chemotherapy, radiotherapy, surgery, immunotherapy and other anti-tumor therapy
Creatinine clearance < 30ml/min
Has received epidermal growth factor targeting therapy
Second malignancy within 5 years(except of Non-melanoma Skin Cancer or carcinoma in situ of cervix)
Serious complications, such as uncontrolled hypertension, coronary heart disease, diabetes, heart failure, etc
Active systemic infection
History of Serious lung or heart disease
Drug or alcohol addiction
Persons without capacity for civil conduct or persons with limited capacity for civil conduct
The patient has physical or mental disorders and is believed to be unable to fully or fully understand the possible complications of the study
To receive chronic systemic immunotherapy or hormone therapy other than this study
Women who are pregnant or breast feeding
Participation in other drugs clinical trials within 1 month
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note